Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

103.61
-0.2600-0.25%
Post-market: 103.610.00000.00%16:30 EST
Volume:1.03M
Turnover:107.83M
Market Cap:6.91B
PE:-33.36
High:109.51
Open:106.36
Low:102.05
Close:103.87
52wk High:122.20
52wk Low:45.91
Shares:66.74M
Float Shares:53.42M
Volume Ratio:1.44
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-4.3376
ROE:-85.79%
ROA:-26.74%
PB:46.46
PE(LYR):-23.89

Loading ...

Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Sale of Common Shares

Reuters
·
6 hours ago

Rhythm Pharmaceuticals CFO to Join Guggenheim Biotech Summit Fireside Chat

Reuters
·
Feb 05

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 20

Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025

Simply Wall St.
·
Jan 19

Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA

TIPRANKS
·
Jan 12

Rhythm Pharmaceuticals Inc : TD Cowen Raises Target Price to $130 From $120

THOMSON REUTERS
·
Jan 12

Rhythm Pharmaceuticals (RYTM) Receives a Buy from TD Cowen

TIPRANKS
·
Jan 10

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 09

BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results

Reuters
·
Jan 09

Rhythm Pharmaceuticals Reports Preliminary 2025 Revenue Up 50% to $194 Million

Reuters
·
Jan 09

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - Prelim Q4 2025 Imcivree Revenues About $57 Mln, up 11% From Q3

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - Topline Data From Phase 3 Emanate Trial Expected Q1 2026

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - FY 2025 Prelim Product Revenues About $194 Mln, up 50% From FY2024

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - March 20, 2026 Pdufa Goal Date for Snda for Setmelanotide in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After an 87% Year-to-Date Biotech Rally

Simply Wall St.
·
Dec 23, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025

Rhythm Pharmaceuticals Director Camille Bedrosian Resigns

Reuters
·
Dec 20, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Dec 17, 2025

Chief Human Resources Officer Pamela J. Cramer Reports Sale of Rhythm Pharmaceuticals Common Shares

Reuters
·
Dec 16, 2025